Real-world Comparative Effectiveness of Rivaroxaban Versus VKA "RIVA-F"


Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- NVAF(non-valvular atrial fibrillation) will be defined as the occurrence of 2 or more inpatient or outpatient claims with ICD(International Classification of Disease)-9 427.31 as the diagnosis code at any time in the patient's data history prior to inclusion
- Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics
- CHA2DS2-Vasc score ≥2 during the 180 days prior to index rivaroxaban use baseline period (CHA2DS2-Vasc: Diabetes mellitus; S2: prior Stroke or TIA or Thromboembolism; V: Vascular disease; A: Age 65-74 years; Sc: Sex category)

Exclusion Criteria

- Patients <18 years of age
- Patients with valvular AF (Atrial fibrillation)
- Pregnancy
- Malignant cancers
- Transient cause of AF
- Patients with venous thromboembolism (pulmonary embolism or deep vein thrombosis)
- Patients with major surgery defined as hip or knee replacement
- Prescriptions of oral anticoagulants (OACs) (apixaban, warfarin, dabigatran, rivaroxaban) before index date
- Prescription of more than one OAC on the index date
- Patient with any of the events defined in the composite endpoint
- Fatal bleeding
- Fatal Stroke/Myocardial infarction
- Intracranial hemorrhage
- Ischemic stroke
- Myocardial infarction